MAZE vs RAPP
MAZE: Maze Therapeutics leverages human genetics data and its Compass platform to discover and develop novel therapeutic candidates across multiple disease indications. RAPP: Rapport Therapeutics is a clinical-stage biotechnology company using a proprietary precision medicine platform to develop targeted therapies for complex neurological and psychiatric disorders.
Side-by-side fundamentals
| Metric | MAZE | RAPP | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $28.49 | $41.33 | |
| Market cap as of 2026-07-23 | $1.6B | $2.1B | |
| PEG as of 2026-07-23 | n/a | -0.90 | |
| Net margin as of 2026-07-23 | +11.0% | n/a | |
| Operating margin as of 2026-07-23 | +34.4% | n/a | |
| ROE as of 2026-07-23 | -36.6% | -24.8% | RAPP higher |
| ROA as of 2026-07-23 | -31.8% | -23.4% | RAPP higher |
| Debt / equity as of 2026-07-23 | 0.11 | 0.00 | RAPP lower |
| Beta as of 2026-07-23 | 1.10 | 2.58 | |
| 1-year return as of 2026-07-22 close | +75.9% | +195.8% | RAPP higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.